Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer
- Twelves, C.
- Awada, A.
- Cortes, J.
- Yelle, L.
- Velikova, G.
- Olivo, M.S.
- Song, J.
- Dutcus, C.E.
- Kaufman, P.A.
Revista:
Breast Cancer: Basic and Clinical Research
ISSN: 1178-2234
Any de publicació: 2016
Volum: 10
Pàgines: 77-84
Tipus: Article
